Skip to main content

Proteostasis Therapeutics Licenses GeneGo's MetaCore

NEW YORK (GenomeWeb News) –GeneGo said today that Proteostasis Therapeutics has licensed its MetaCore curated data mining and analysis platform.

Proteostasis Therapeutics is developing small molecule therapeutics based on studies of the human proteostasis network, the balance of proteins that can protect the body from diseases, GeneGo said. Deficiencies in that network can lead to a range of diseases, such as emphysema, type II diabetes, Alzheimer's disease, and Huntington's disease, said GeneGo.

St. Joseph, Mich.-based GeneGo is developing pathway reconstruction maps for a number of diseases, including neurodegenerative disorders.

Proteostasis Therapeutics will use MetaCore's curated database of protein interactions in its protein characterization-focused efforts to discover small molecules that could be used to treat diseases.

Financial terms of the agreement were not released.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.